Extended Data Fig. 5: Investigator-assessed response rates per RECIST v1.1 at ad hoc analysis in the (A) pMMR and (B) dMMR populations. | Nature Medicine

Extended Data Fig. 5: Investigator-assessed response rates per RECIST v1.1 at ad hoc analysis in the (A) pMMR and (B) dMMR populations.

From: Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

Extended Data Fig. 5

Analysis included patients in the intention-to-treat population with measurable disease at baseline. Data cutoff date: August 18, 2023. Data shown are the mean ORR and 95% CIs based on the binomial exact method. CR, complete response; CT, chemotherapy; dMMR, mismatch repair-deficient; ORR, objective response rate; pMMR, mismatch repair-proficient; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.

Back to article page